Submit Deal

COMMODORE CAPITAL

HQ - New York, NY

Summary

Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.

Deals Overview

Total Deals7

Valued Deals7

Total Value£ 946 M

Avg. Deal Size£ 135 M

Market Context

Senior Management

Michael Kramarz
Managing Partner
Egen Atkinson
Founding Partner

Sort

24 Aug 2020|United States|Pharmaceuticals

Target: KRONOS BIO

Bidder: PERCEPTIVE ADVISORS LLC

18 Service Providers

3 Target | 15 Bidder

18 Dealmakers

3 Target | 15 Bidder

£ 118 M

Value

16 Jun 2020|United States|Biotechnology

Target: C4 THERAPEUTICS INC

Bidder: RTW INVESTMENTS

16 Service Providers

5 Target | 11 Bidder

26 Dealmakers

3 Target | 22 Bidder

£ 119 M

Value

28 Oct 2020|United States|Biotechnology

Target: MIRAGEN THERAPEUTICS

Bidder: VENROCK

16 Service Providers

5 Target | 11 Bidder

19 Dealmakers

5 Target | 14 Bidder

£ 70 M

Value

02 Nov 2021|United States|Biotechnology

Target: SHORELINE BIOSCIENCES

Bidder: EVENTIDE ASSET MANAGEMENT

4 Service Providers

2 Target | 2 Bidder

5 Dealmakers

2 Target | 3 Bidder

£ 102 M

Value

09 Aug 2023|United States|Biotechnology

Target: ADARX PHARMACEUTICALS

Bidder: BAIN CAPITAL LIFE SCIENCES

3 Service Providers

1 Target | 2 Bidder

4 Dealmakers

2 Target | 2 Bidder

£ 156 M

Value

14 Feb 2024|United States|Biotechnology

Target: COGENT BIOSCIENCES

Bidder: REDMILE GROUP

5 Service Providers

5 Target

3 Dealmakers

3 Target

£ 284 M

Value

07 Aug 2024|United States|Biotechnology

Target: IDRX

Bidder: ANDREESSEN HOROWITZ LLC (A16Z)

12 Service Providers

2 Target | 10 Bidder

11 Dealmakers

2 Target | 9 Bidder

£ 94 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy